COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study
Authors
Allsup, D.Howard, D.
Emmerson, J.
Hockaday, A.
Rawstron, A.
Oughton, J. B.
Bloor, Adrian
Phillips, D.
Nathwani, A.
Paneesha, S.
Turner, D.
Munir, T
Hillmen, P.
Affiliation
Haematology, Hull University Teaching Hospital, Kingston upon Hull, UK.Issue Date
2021
Metadata
Show full item recordAbstract
NoneCitation
Allsup D, Howard D, Emmerson J, Hockaday A, Rawstron A, Oughton JB, et al. COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study. Br J Haematol. 2021 May 24.Journal
British Journal of HaematologyDOI
10.1111/bjh.17526PubMed ID
34028800Additional Links
https://dx.doi.org/10.1111/bjh.17526Type
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.1111/bjh.17526
Scopus Count
Collections
Related articles
- Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial.
- Authors: Howard DR, Munir T, Hockaday A, Rawstron AC, Collett L, Oughton JB, Allsup D, Bloor A, Phillips D, Hillmen P
- Issue date: 2016 Sep 20
- Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
- Authors: Stilgenbauer S, Bosch F, Ilhan O, Kisro J, Mahé B, Mikuskova E, Osmanov D, Reda G, Robinson S, Tausch E, Turgut M, Wójtowicz M, Böttcher S, Perretti T, Trask P, Van Hoef M, Leblond V, Foà R
- Issue date: 2021 Apr
- [Chronic lymphocytic leukemia].
- Authors: Aoki S
- Issue date: 2014 Feb
- Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.
- Authors: Cramer P, von Tresckow J, Fink AM, Robrecht S, Giza A, Tausch E, Müller L, Knauf W, Zingerle M, Al-Sawaf O, Langerbeins P, Fischer K, Kreuzer KA, Kneba M, Wendtner CM, Stilgenbauer S, Eichhorst B, Hallek M
- Issue date: 2024 Jun
- First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
- Authors: Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, Köppler H, Kiehl M, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Trneny M, Fischer K, Döhner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Stilgenbauer S, Böttcher S, Hallek M, international group of investigators, German CLL Study Group (GCLLSG)
- Issue date: 2016 Jul